Who are Acarbose (Glucobay, BAYG5421)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Glyset, Precose, sitagliptin and acarbose, Voglibose (Basen), Mulberry Leaf Extract, Glucobay (acarbose).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acarbose-glucobay-bayg5421.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Acarbose (Glucobay, BAYG5421) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acarbose (Glucobay, BAYG5421) (Acarbose (Glucobay, BAYG5421)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-glucosidase inhibitor. Area: Diabetes.

marketed Alpha-glucosidase inhibitor Alpha-glucosidase enzymes (intestinal brush border) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Acarbose (Glucobay, BAYG5421) (Acarbose (Glucobay, BAYG5421)) — Bayer. Acarbose inhibits intestinal alpha-glucosidase enzymes to slow the digestion and absorption of carbohydrates, reducing postprandial blood glucose spikes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acarbose (Glucobay, BAYG5421) TARGET	Acarbose (Glucobay, BAYG5421)	Bayer	marketed	Alpha-glucosidase inhibitor	Alpha-glucosidase enzymes (intestinal brush border)
Glyset	MIGLITOL	Pfizer	marketed	alpha-Glucosidase Inhibitor	Lysosomal alpha-glucosidase	1996-01-01
Precose	ACARBOSE	Bayer	marketed	alpha-Glucosidase Inhibitor [EPC]	Sucrase-isomaltase, intestinal	1995-01-01
sitagliptin and acarbose	sitagliptin and acarbose	Nanjing First Hospital, Nanjing Medical University	marketed	DPP-4 inhibitor + alpha-glucosidase inhibitor combination	DPP-4 enzyme; alpha-glucosidase enzymes
Voglibose (Basen)	Voglibose (Basen)	Bayer	marketed	Alpha-glucosidase inhibitor	Alpha-glucosidase enzymes
Mulberry Leaf Extract	Mulberry Leaf Extract	University of Mississippi Medical Center	marketed	Alpha-glucosidase inhibitor	Alpha-glucosidase enzymes (intestinal disaccharidases)
Glucobay (acarbose)	Glucobay (acarbose)	Zealand University Hospital	marketed	Alpha-glucosidase inhibitor	Alpha-glucosidase enzymes (maltase, isomaltase, sucrase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-glucosidase inhibitor class)

Bayer · 2 drugs in this class
EMS · 2 drugs in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Sanofi · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class
University of Alabama at Birmingham · 1 drug in this class
University of Mississippi Medical Center · 1 drug in this class
Zealand University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acarbose (Glucobay, BAYG5421) — Competitive Intelligence Brief. https://druglandscape.com/ci/acarbose-glucobay-bayg5421. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab